Ziltivekimab and the ZEUS Miss: When Crushing Inflammation Didn't Save the Heart (August 24, 2026)
Table of Contents
- A different way to protect the heart
- The idea: 'residual inflammatory risk'
- Why IL-6, and why ziltivekimab
- The promise: RESCUE crushed the marker
- The test: ZEUS, HERMES, ARTEMIS
- The result: engagement without benefit
- Safety: the cost of blocking IL-6
- What the miss means for the inflammation hypothesis
- How it fits the wider cardiovascular pipeline
- Bottom line and cautions
A different way to protect the heart
Almost everything modern cardiology does to prevent heart attacks works through cholesterol - statins, ezetimibe, PCSK9 drugs like inclisiran, and the newer lipoprotein(a) and ApoC-III silencers. Ziltivekimab was built to test a fundamentally different lever: inflammation. It is a fully human monoclonal antibody that mops up interleukin-6 (IL-6), a pro-inflammatory cytokine, given as a small once-monthly injection under the skin. The hope was that calming the smoldering inflammation inside artery walls could prevent heart attacks and strokes even in people whose LDL cholesterol is already well controlled. On July 31, 2026, the pivotal ZEUS trial gave that hope a blunt reality check.
The idea: 'residual inflammatory risk'
Cardiologists have long noticed that many patients keep having events despite excellent cholesterol numbers. A blood marker called high-sensitivity C-reactive protein (hsCRP) flags these people - it rises when the body is inflamed. The turning point was the CANTOS trial (2017), which showed that canakinumab, an antibody against interleukin-1 beta, reduced recurrent cardiovascular events in heart-attack survivors with high hsCRP - without touching their cholesterol. That was the first hard proof that fighting inflammation alone could protect the heart. Canakinumab itself was never commercialized for heart disease, but it lit the fuse. The concept earned a name: 'residual inflammatory risk.'
Why IL-6, and why ziltivekimab
Inflammation runs as a cascade: IL-1 beta switches on IL-6, and IL-6 tells the liver to pump out CRP, fibrinogen and other troublemakers. Ziltivekimab targets IL-6, one rung lower than canakinumab, on the theory that this would be a cleaner, more direct way to shut down the vascular-inflammation signal. Unusually, it binds the IL-6 cytokine itself rather than its receptor. It was originally developed by a small company, Corvidia Therapeutics, and specifically tuned for people with chronic kidney disease (CKD) - a group with unusually high inflammation and cardiovascular risk. Novo Nordisk, best known for GLP-1 drugs, bought Corvidia in 2020 for up to $2.1 billion to move into cardiovascular disease.
The promise: RESCUE crushed the marker
The Phase 2 RESCUE trial, led by Paul Ridker and published in The Lancet in 2021, looked spectacular on paper. In patients with moderate-to-severe CKD and elevated hsCRP, ziltivekimab lowered hsCRP by up to about 92%, versus roughly 4% on placebo, along with favorable moves in fibrinogen and lipoprotein(a). Few drugs move an inflammatory marker that hard. If hsCRP were truly a lever on outcomes - and not just a bystander - ziltivekimab looked ideally placed to pull it. That result justified one of the biggest bets in anti-inflammatory cardiology: a three-trial Phase 3 outcomes program.
The test: ZEUS, HERMES, ARTEMIS
Novo Nordisk launched three large Phase 3 cardiovascular outcomes trials, all using once-monthly ziltivekimab 15 mg versus placebo. ZEUS enrolled more than 6,300 adults with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation (hsCRP at or above 2 mg/L), following them up to four years for three-point MACE - cardiovascular death, non-fatal heart attack or non-fatal stroke. HERMES targets heart failure with preserved or mildly reduced ejection fraction and elevated hsCRP. ARTEMIS studies patients right after an acute heart attack. ZEUS was the flagship - the trial designed to prove or disprove the whole idea.
The result: engagement without benefit
On July 31, 2026, Novo Nordisk announced that ZEUS missed its primary endpoint. The drug did exactly what it was supposed to do biochemically - free IL-6 and hsCRP fell as expected, confirming it hit its target. But that did not translate into fewer heart attacks, strokes or cardiovascular deaths. The hazard ratio was 0.99 (95% CI 0.88-1.11) - essentially no difference from placebo. It is the sharpest possible version of a scientist's nightmare: the mechanism worked, the biomarker moved, and the patients didn't benefit. Novo Nordisk said it would take a non-cash impairment charge in the third quarter of 2026 while keeping its full-year profit outlook unchanged.
Safety: the cost of blocking IL-6
Overall safety was broadly similar between ziltivekimab and placebo, with one expected exception: serious infections were more common on the active drug. That is a well-known class effect of dampening IL-6 signaling, which is part of how the body fights infection - the same trade-off seen with IL-6-pathway drugs used in rheumatology. In a trial where the hoped-for benefit did not appear, that infection signal weighs more heavily in the risk-benefit ledger.
What the miss means for the inflammation hypothesis
ZEUS is being read as a setback for the broader 'inflammation hypothesis' of atherosclerosis. It sharpens a long-running question: is hsCRP a driver of cardiovascular events, or just a marker that travels alongside them? CANTOS suggested inflammation was causal; ZEUS - with a drug that hammered the marker even harder - suggests the story is more complicated, at least in stable atherosclerotic disease with CKD. It does not close the book. IL-6 inhibition might still help where inflammation plays a more acute or mechanical role, which is exactly what HERMES (heart failure) and ARTEMIS (the immediate aftermath of a heart attack) are designed to find out. Both continue, with topline readouts expected in the first half of 2027.
How it fits the wider cardiovascular pipeline
Ziltivekimab sits alongside a wave of injectable and RNA-based cardiovascular drugs profiled on PepTracker Pro that attack residual risk from other angles: PCSK9-lowering inclisiran, the lipoprotein(a) silencers pelacarsen, olpasiran, lepodisiran and zerlasiran, the ApoC-III drugs olezarsen and plozasiran, the oral Lp(a) and CETP agents muvalaplin and obicetrapib, and metabolic heavyweights like semaglutide whose cardiovascular benefit may itself be partly anti-inflammatory. Most of those target lipids; ziltivekimab was the purest test of the inflammation axis. Its stumble makes the lipid-lowering and metabolic strategies look, for now, like the more reliable path to fewer events - while leaving inflammation an open, unfinished question.
Bottom line and cautions
Ziltivekimab is an investigational anti-IL-6 antibody, not an approved medicine and not a supplement - any product sold under its name outside a clinical trial is unverified and unsafe. It proved it could crush inflammatory markers but, in the pivotal ZEUS trial, did not reduce cardiovascular events, and it carries a real signal of serious infection. Whether IL-6 blockade earns a place in cardiology now rests on HERMES and ARTEMIS in 2027. For now, ziltivekimab stands as one of the most instructive 'negative' results in recent cardiovascular research - a reminder that moving a biomarker, even dramatically, is not the same as helping a patient. This article is educational and not medical advice.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation (July 31, 2026) Source
- [2] ZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients - tctmd.com Source
- [3] Ziltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial - HCPLive Source
- [4] IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): phase 2 trial - Lancet 2021 (PubMed) Source
- [5] Novo setback casts doubt on a new way to treat heart disease - BioPharma Dive Source
- [6] Novo Nordisk moves further into CV diseases with Corvidia acquisition (2020) - Pharmaceutical Technology Source
Related Articles
Pelacarsen: The First Drug That Could Prove Lowering Lp(a) Saves Lives — Inside the Landmark Lp(a)HORIZON Readout (August 5, 2026)
About one in five people inherit high lipoprotein(a) — a hidden, genetic driver of heart attacks and strokes that no diet, statin, or PCSK9 inhibitor can touch. Pelacarsen, an antisense oligonucleotide from Ionis and Novartis, cuts it by roughly 80% at the source. Its Lp(a)HORIZON trial (8,323 patients) is the first outcomes study ever to test whether lowering Lp(a) prevents cardiovascular events — and the readout is landing in 2026.
Inclisiran (Leqvio): The Twice-a-Year siRNA Injection That Halves LDL Cholesterol - How PCSK9 Silencing Works and Where the Outcomes Data Stand (August 17, 2026)
Statins and daily pills lose their power when patients stop taking them. Inclisiran (Leqvio) takes a different route: a subcutaneous injection given just twice a year that silences the liver protein PCSK9 and cuts LDL cholesterol by about half. It was the first RNA-interference medicine approved for a common chronic cardiovascular condition, and in 2025 the FDA broadened its label to first-line use. Here is how PCSK9 silencing works, what the ORION trials showed, how inclisiran compares with the PCSK9 antibodies, and why the VICTORION outcomes trials are the test that still matters.
Eplontersen (Wainua): The Antisense TTR Silencer That Missed in the Heart - What CARDIO-TTRansform Means Next to Vutrisiran's Success (August 23, 2026)
Vutrisiran silenced TTR and moved mortality. Eplontersen silences the same protein a different way - as an antisense oligonucleotide - and in July 2026 its huge ATTR cardiomyopathy trial, CARDIO-TTRansform, missed its primary endpoint. Here is how Ionis and AstraZeneca's once-monthly Wainua works, why it succeeded in nerves but stumbled in the heart, and what the monotherapy signal tells us about adding a silencer on top of tafamidis.